Business Wire

PA-EXONE

5.8.2020 14:02:13 CEST | Business Wire | Press release

Share
ExOne Qualifies Inconel 718 for Binder Jet 3D Printing, Now Offers 22 Materials

The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that the nickel-based alloy Inconel 718 has been certified as Third-Party Qualified, the company’s highest designation of material readiness for its metal 3D printers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200805005200/en/

Frequently used in the aerospace, energy and automotive industries, Inconel 718 is known for high strength and hardness, with strong resistance to corrosion, chemicals and extreme temperatures ranging from sub-zero to 1300° F. It also has outstanding welding characteristics, and is often used for high-temperature applications, such as jet engines and tooling, or corrosive environments, such as those featuring seawater or acids.

“Today’s qualification of Inconel 718, following on the heels of M2 Tool Steel earlier this year, shows the ExOne R&D team is aggressively delivering new materials for binder jet 3D printing,” said Rick Lucas, ExOne CTO and VP, New Markets. “Our increasing pace of material qualifications is a testament to the strength of our new metal 3D printer systems equipped with Triple ACT, an advanced compaction technology that is essential for binder jetting metals and other materials at high speeds and densities.”

As is the case with Inconel 718, ExOne’s patented Triple ACT enables 3D printing of standard MIM powders, followed by standard sintering profiles and heat treatments, that deliver high-density results consistent with wrought material. Independent testing verifies that Inconel 718 3D printed and sintered by ExOne meets ASTM standard B637-18 .

“ExOne can now transition R&D materials to full qualification as demand increases,” Lucas noted.

ExOne Material Qualification Levels

ExOne has three tiers of material qualification, to signify the varying levels of readiness of materials for binder jet 3D printing applications: R&D, Customer-Qualified and Third-Party Qualified.

Previously, ExOne had recognized Inconel 718 as an R&D material, which meant it had been deemed printable for researchers, supported by ongoing development. The new Third-Party Qualified status means that the material has passed rigorous ExOne tests over multiple builds and has verified material property data from an independent third party.

Customer-Qualified materials are those that have been qualified by ExOne customers with their own standards and are being successfully printed today for their own applications. However, they have not yet earned ExOne’s highest level of qualification for general market readiness.

ExOne has an aggressive roadmap to qualify new materials based on customer demand, and frequently works with major manufacturers to develop new materials to suit specific applications.

To date, 22 metal, ceramic and composite materials are now Third-Party or Customer-Qualified. The full list is available at www.exone.com/metalmaterials .

Additionally, more than two-dozen materials are recognized as R&D ready, including aluminum, which has been fast-tracked for qualification. ExOne believes the ability to 3D print aluminum at high speeds will have a transformative, sustainable effect on the automobile and aerospace industry.

CleanFuse Enables Binder Jetting of Premium Metals

ExOne’s proprietary CleanFuse binder was a critical component in the new qualification of Inconel 718. CleanFuse is a clean-burning binder for 3D printing metals that are sensitive to carbon left behind by other binding agents during sintering.

Binder jetting is a 3D printing process that uses a digital file to quickly inkjet a binder into a bed of powder particles — metal, sand or ceramic — creating a solid part one layer at a time. When printing metals, the final part must be sintered in order to fuse the particles together into a solid object.

When binders don’t burn off cleanly during sintering, carbon residue can alter the chemistry and fundamental performance of some sensitive metals. Consequently, a benefit of 3D printing metals with CleanFuse is preserving consistent part performance, including a part’s ability to be welded. This is critical for aerospace, automotive or defense applications, where parts are often integrated or assembled into a final product.

About ExOne

ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye